MBX Biosciences, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 55.87 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.69B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Details
| Name | MBX Biosciences, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 63 |
| Founded | 2018 |
| Ipo Date | 2024-09-13 |
| Ceo | Steven Hoerter |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 16.00 |
| Isin | US55287L1017 |
| Cusip | 55287L101 |
| Cik | 1776111 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Steven L. Hoerter | Executive Chairperson, Chief Executive Officer and President |
| Dr. Salomon Azoulay M.D. | Chief Medical Officer |
| John W. Smither CPA | Chief Financial Officer |
| Pete De Spain | Senior Vice President of Investor Relations and Corporate Communications |
| Jeffrey Held J.D. | Chief Legal Officer |
| Michelle Graham | Chief Human Resources Officer |
| Dr. Michael A. Dorato DABT, Ph.D. | Senior Vice President of Discovery and Non-Clinical Development |
| Dr. Chatan Charan Ph.D. | Senior Vice President of Pharmaceutical Development and Chemistry, Manufacturing and Controls |
| Mark Hope | Chief Regulatory and Quality Officer |
| Dr. Andreas Moraitis M.D. | Senior Vice President of Clinical Development |
Contact
| Address | 11711 North Meridian Street, Suite 300, Carmel, Indiana 46032, United States |
| Phone | 317 659 0200 |
| Website | https://mbxbio.com |